AU2018328773B2 - Combination therapies for inhibition of Polo-like Kinase 4 - Google Patents

Combination therapies for inhibition of Polo-like Kinase 4 Download PDF

Info

Publication number
AU2018328773B2
AU2018328773B2 AU2018328773A AU2018328773A AU2018328773B2 AU 2018328773 B2 AU2018328773 B2 AU 2018328773B2 AU 2018328773 A AU2018328773 A AU 2018328773A AU 2018328773 A AU2018328773 A AU 2018328773A AU 2018328773 B2 AU2018328773 B2 AU 2018328773B2
Authority
AU
Australia
Prior art keywords
inhibitor
antibody
cancer
cfi
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2018328773A
Other languages
English (en)
Other versions
AU2018328773A1 (en
Inventor
Mark R. Bray
Graham Fletcher
Tak Wah Mak
Jacqueline M. Mason
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University Health Network
Original Assignee
University Health Network
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University Health Network filed Critical University Health Network
Publication of AU2018328773A1 publication Critical patent/AU2018328773A1/en
Application granted granted Critical
Publication of AU2018328773B2 publication Critical patent/AU2018328773B2/en
Priority to AU2024200937A priority Critical patent/AU2024200937A1/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Mycology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Plural Heterocyclic Compounds (AREA)
AU2018328773A 2017-09-08 2018-09-07 Combination therapies for inhibition of Polo-like Kinase 4 Ceased AU2018328773B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2024200937A AU2024200937A1 (en) 2017-09-08 2024-02-14 Combination therapies for inhibition of Polo-like Kinase 4

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762555718P 2017-09-08 2017-09-08
US62/555,718 2017-09-08
PCT/CA2018/051086 WO2019046949A1 (en) 2017-09-08 2018-09-07 POLYTHERAPIES FOR INHIBITING KINASE 4 OF THE POLO TYPE

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2024200937A Division AU2024200937A1 (en) 2017-09-08 2024-02-14 Combination therapies for inhibition of Polo-like Kinase 4

Publications (2)

Publication Number Publication Date
AU2018328773A1 AU2018328773A1 (en) 2020-03-26
AU2018328773B2 true AU2018328773B2 (en) 2023-11-16

Family

ID=65633360

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2018328773A Ceased AU2018328773B2 (en) 2017-09-08 2018-09-07 Combination therapies for inhibition of Polo-like Kinase 4
AU2024200937A Abandoned AU2024200937A1 (en) 2017-09-08 2024-02-14 Combination therapies for inhibition of Polo-like Kinase 4

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2024200937A Abandoned AU2024200937A1 (en) 2017-09-08 2024-02-14 Combination therapies for inhibition of Polo-like Kinase 4

Country Status (8)

Country Link
US (1) US12109215B2 (https=)
EP (1) EP3678669A4 (https=)
JP (2) JP7343483B2 (https=)
CN (1) CN111225670A (https=)
AU (2) AU2018328773B2 (https=)
CA (1) CA3074876A1 (https=)
TW (1) TWI845482B (https=)
WO (1) WO2019046949A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9273283B2 (en) * 2009-10-29 2016-03-01 The Trustees Of Dartmouth College Method of producing T cell receptor-deficient T cells expressing a chimeric receptor
JP2023505301A (ja) * 2019-12-06 2023-02-08 ユニバーシティー ヘルス ネットワーク 急性骨髄性白血病または骨髄異形成症候群に対する治療
US20230165871A1 (en) * 2020-04-06 2023-06-01 University Health Network Combination therapies for inhibition of polo-like kinase 4
MX2023013225A (es) 2021-05-11 2024-01-15 Oric Pharmaceuticals Inc Inhibidores de la cinasa 4 similar a polo.
WO2022266240A1 (en) * 2021-06-16 2022-12-22 Onconova Therapeutics, Inc. Methods and compositions for treating cancer

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2963281A1 (en) * 2014-10-03 2016-04-07 Novartis Ag Combination therapies

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5442906B2 (ja) * 2010-04-06 2014-03-19 ユニバーシティ・ヘルス・ネットワーク キナーゼインヒビターおよびこれを用いた癌の治療方法
US8933070B2 (en) * 2010-07-02 2015-01-13 University Health Network Methods of targeting PTEN mutant diseases and compositions therefor
WO2012048411A1 (en) * 2010-10-13 2012-04-19 University Health Network Plk-4 inhibitors and method of treating cancer with same
RS58413B1 (sr) * 2013-10-18 2019-04-30 Univ Health Network So i kristalni oblici inhibitora plk-4
SG11201602882VA (en) * 2013-10-18 2016-05-30 Univ Health Network Treatment for pancreatic cancer
ES2686549T3 (es) * 2014-06-16 2018-10-18 Worldwide Innovative Network Método para seleccionar una triterapia personalizada para el tratamiento del cáncer
EP3981430A1 (en) * 2015-01-21 2022-04-13 Memorial Sloan Kettering Cancer Center Methods and compositions for increasing susceptibility to radiation treatment by inhibiting suppression of numerical chromosomal instability of cancer cells
AU2016219204B2 (en) * 2015-02-12 2021-01-21 Beyondspring Pharmaceuticals, Inc. Use of Plinabulin in combination with immune checkpoint inhibitors

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2963281A1 (en) * 2014-10-03 2016-04-07 Novartis Ag Combination therapies

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
SAMPSON ET AL.,"The Discovery of Polo-Like Kinase 4 Inhibitors: Identification of .. (CFI-400945) as a Potent, Orally Active Antitumor Agent", J Med Chem, vol. 58, (1), 147-169 *
WOUTERS ET AL., CANCER IMMUNOL. IMMUNOTHER., vol. 66, 13 April 2017 (2017-04-13), pages 811 - 818 *

Also Published As

Publication number Publication date
WO2019046949A1 (en) 2019-03-14
JP2020533293A (ja) 2020-11-19
US20210060026A1 (en) 2021-03-04
US12109215B2 (en) 2024-10-08
JP7343483B2 (ja) 2023-09-12
EP3678669A4 (en) 2021-06-09
TW201919637A (zh) 2019-06-01
EP3678669A1 (en) 2020-07-15
CN111225670A (zh) 2020-06-02
TWI845482B (zh) 2024-06-21
AU2018328773A1 (en) 2020-03-26
AU2024200937A1 (en) 2024-02-29
CA3074876A1 (en) 2019-03-14
JP2023155459A (ja) 2023-10-20

Similar Documents

Publication Publication Date Title
AU2022200196B2 (en) Methods, compositions, and kits for treatment of cancer
AU2024200937A1 (en) Combination therapies for inhibition of Polo-like Kinase 4
CN107743401B (zh) 包含抗pd-1抗体和另外的抗体的组合的组合物
JP2023039448A (ja) がんを治療するための、ｐｄ－１アンタゴニスト及びｖｅｇｆｒ／ｆｇｆｒ／ｒｅｔチロシンキナーゼ阻害剤の組合せ
KR20200142542A (ko) Cd73 길항제 항체 및 pd-1/pd-l1 축 길항제 항체에 의한 항암 조합 요법
US12110337B2 (en) Anti-CD27 antibodies and uses thereof
CA3141531A1 (en) Combination therapies using cdk inhibitors
US20230390294A1 (en) Combination therapies for inhibition of ttk protein kinase
US20220025061A1 (en) Combination therapies for treating disease using an innate immunity modifier and an ox40 agonist
CN111973739A (zh) 抗pd-l1单克隆抗体治疗癌症的用途
CN115087461A (zh) 使用pd-1拮抗剂、ilt4拮抗剂和化学治疗剂的组合治疗癌症的方法
CA3128521A1 (en) Administration of sumo-activating enzyme inhibitor and checkpoint inhibitors
US20230192856A1 (en) Dosing and administration of activatable anti-ctla-4 antibody
CN113164599B (zh) 抗pd-l1单克隆抗体治疗癌症的用途
WO2023192478A1 (en) Combination therapy with anti-il-8 antibodies and anti-pd-1 antibodies for treating cancer
CN118829446A (zh) 使用ctla-4和pd-1双特异性抗体的治疗方法

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired